- Open Access
Critical role of endogenous histamine in promoting end-organ tissue injury in sepsis
© The Author(s). 2016
- Received: 28 July 2016
- Accepted: 29 October 2016
- Published: 8 November 2016
Histamine assumes an important role as a major mediator in various pathologic disorders associated with inflammation and immune reactions. However, the involvement of histamine in the pathological conditions and symptoms of sepsis remains entirely unknown. In this study, we establish that histamine is identified as a contributory mediator to promoting the development of organ injury in sepsis.
Histidine decarboxylase (HDC) gene knockout (HDC−/−) mice, histamine H1-/H2-receptor gene-double knockout (H1R−/−/H2R−/−) mice, and their littermate wild-type (WT) C57BL/6J mice underwent cecal ligation and puncture (CLP) or sham operation. Some WT mice were injected intraperitoneally with d-chlorpheniramine and famotidine 60 min before CLP to block H1- and H2-receptors, respectively.
In mice rendered septic by CLP, tissue histamine levels were elevated in association with increased HDC expression. Sepsis-induced abnormal cytokine production and multiple organ injury (lung, liver, and kidney) were significantly less pronounced in HDC−/− mice as compared with WT controls, and HDC deficiency had improved survival in sepsis. This benefit corresponded with a significant reduction in activation levels of the nuclear factor (NF)-κB signaling pathway. H1R−/−/H2R−/− mice apparently behaved similar to HDC knockout mice in reducing sepsis-related pathological changes. Pharmacological interventions with H1- and H2-receptor antagonists indicated that both H1- and H2-receptors were involved in septic lung and liver injury, whereas only H2-receptors contributed to septic kidney injury.
In the setting of sepsis, histamine, through activation of H1- and H2-receptors, serves as an aggravating mediator to contribute to the development of sepsis-driven major end-organ failure.
- Histidine decarboxylase
- Organ injury
Sepsis is a common and potentially life-threatening medical condition in populations in intensive care units (ICU). Despite advances in overall care of critically ill patients, sepsis remains the primary cause of death from microbial infections [1, 2]. The development of a failure of one or more organs, including the lung, kidney, and liver, poses a major threat to the survival of patients with sepsis. In accordance with the importance of more timely management of patients with sepsis or at risk of developing sepsis, sepsis is now defined as life-threatening organ dysfunction due to a dysregulated host response to infection . The pathogenesis of sepsis-induced organ failure has been extensively gleaned from animal models and human studies [4–6], but the mechanisms underlying the pathophysiologic processes that both initiate and promulgate organ dysfunction in sepsis have not been fully elucidated. A greater understanding of the mechanisms that underlie the development of organ dysfunction in sepsis may enable us to develop therapies targeted at preventing or limiting molecular events associated with the progress of fatal organ failure and, hence, leading to improved outcomes.
In a prospective, controlled, clinical study, elevated plasma histamine levels have been shown to be causally associated with sepsis . In our previous studies, the sustained elevation of plasma histamine has been shown to be associated with the time-dependent increase in expression of histidine decarboxylase (HDC), which is the catabolic enzyme of histamine synthesis, in the animals with lipopolysaccharide (LPS)- and cecal ligation and puncture (CLP)-induced sepsis [8–10]. Furthermore, endotoxemia may cause superinduction of H1- and H2-receptors in cardiovascular and pulmonary tissues [8, 9, 11]. Since histamine mediates a wide range of cellular responses, including allergic and inflammatory reactions, gastric acid secretion, vascular tone and permeability, and neurotransmission in the central nervous system , the histamine biological responsiveness may be of special importance in certain pathological aspects suggestive of histamine release. It would be thus allowable to assume that histamine may play a contributory role in the development of major organ dysfunction and failure associated with sepsis.
In the present study, we examined whether genetic and pharmacological interventions of histamine can provide a change in systemic inflammation and organ injury in mice with CLP-induced polymicrobial sepsis in order to explore the role of histamine in the pathophysiology of the septic syndrome. CLP-induced sepsis is an animal model that has high relevance to humans because it reproduces many hallmarks of sepsis that occur in patients . We applied HDC gene knockout (HDC−/−) mice , lacking histamine, to investigate the effect of histamine deficiency on the pathophysiology of CLP-induced sepsis. Along with HDC−/− mice, we also used histamine H1-/H2-receptor gene-double knockout (H1R−/−/H2R−/−) mice generated by crossbreeding of H1-receptor null mice and H2-receptor null mice. Finally, we tested changes in the pathophysiological features of CLP-induced sepsis by pharmacological antagonism of H1- and H2-receptors.
Generation of HDC−/− mice and H1R−/−/H2R−/− mice
HDC−/− mice were generated according to previously described procedures . H1-receptor gene deficient mice and H2-receptor gene deficient mice were a gift from Prof. Kazuhiko Yanai, Tohoku University [15, 16], and the progeny of the colony was maintained. Serially breeding of these two strains generated the double-knockout line (H1R−/−/H2R−/−). Genotyping of the resultant mice was determined by PCR analysis of DNA extracted from tail samples. HDC−/− mice and H1R−/−/H2R−/− mice were of a genetic background of a C57BL/6 J strain, and their littermates were used as wild-type (WT) controls. Mice were housed under specific-pathogen-free conditions.
Animal model of sepsis
All animal studies were conducted in accordance with the National Institute of Health Guidelines on the use of laboratory animal and with approval of the Care and Use Committee of the University of Toyama. The surgical procedure to generate CLP-induced sepsis was performed as described elsewhere [17–19]. In brief, male mice, 8–10 weeks old, were anesthetized with 3–4% sevoflurane, and a middle abdominal incision was made. The cecum was mobilized, ligated, and punctured twice with a 21-gauge needle, allowing exposure of faces, the bowel was repositioned, and the abdomen was closed with sterile suture. Sham-operated control underwent the same procedure except for ligation and puncture of the cecum. Some WT mice were injected intraperitoneally with a single dose of d-chlorpheniramine (10 mg/kg) and famotidine (20 mg/kg) 60 min before CLP to block H1- and H2-receptors, respectively. A noninvasive computerized tail-cuff system was used for measuring blood pressure and heart rate in mice [17, 20].
Measurement of histamine
The amount of histamine was determined by the fluorometrical method with o-phthalaldehyde . The tissues were homogenized in 4–5 volumes of PBS containing 2 M NaCl, lysed using 0.5% Triton X-100, and centrifuged at 12,000×g for 30 min at 4 °C in order to obtain the soluble fraction for histamine assay.
RNA extraction and quantitative real-time PCR
Total RNA was isolated from tissues with Sepazol-RNA I Super G (Nacalai Tesque, Kyoto, Japan). PrimeScript RT Master Mix (Takara Bio, Ohtsu, Japan) or ReverTra Ace qPCR RT Master Mix (Toyobo, Osaka, Japan) was used for the reverse transcription reaction, and real-time PCR analyses were performed using SYBR Premix Ex Taq II (Tli RNaseH Plus), ROX plus (Takara Bio). Values were normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) according to the manufacturer’s protocol (MX3000P real-time PCR system; Agilent Technologies Inc., Santa Clara, CA, USA).
Blood was collected in serum gel tubes (Sarsted, Nümbrecht, Germany), and serum was obtained and stored at −80 °C. The quantitative determination of aspartate aminotransferase (AST), alanine aminotransferase (ALT), blood urea nitrogen (BUN), and creatinine in serum was made on Hitachi 7180 Biochemistry Automatic Analyzer (Hitachi High-Technologies, Tokyo, Japan). Interleukin (IL)-1β, IL-6, tumor necrosis factor (TNF)-α, and monocyte chemotactic protein (MCP)-1 were measured by the use of a commercially available enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems, Minneapolis, MN, USA), according to the manufacturer’s instructions. The plate was read on a microplate reader (Nippon-InterMed, Tokyo, Japan). Assays were performed in duplicate.
Lung wet-to-dry weight ratio
Surgically removed lung tissues were blotted dry and weighed to determine the lung wet weight. The lung tissues were then wrapped loosely in aluminum foil, placed in a drying oven overnight, and weighed again for calculation of the wet-to-dry weight ratio [9, 22].
Tissues were fixed by immersion in 10 % buffered formaldehyde overnight, embedded in paraffin, and cut into 4-μm-thick sections. After deparaffinization, slides were stained with hematoxylin and eosin by standard methods. All the histological studies were performed in a blinded fashion. A semiquantitative morphometric analysis of lung injury was performed by scoring from 0 to 4 (none, light, moderate, severe, very severe) for the following categories: neutrophil infiltration, pulmonary edema, and disorganization of lung parenchyma and hemorrhage . A total lung injury score was calculated by adding the individual scores in every animal and averaging the total values in each group.
Tissue sections (4 μm) were rehydrated, and endogenous peroxidases were quenched with 3% hydrogen peroxide. Slides were then incubated overnight at 4 °C with primary antibodies for myeloperoxidase (MPO; 1:200 dilution; Abcam, Cambridge, MA, USA), or neutrophil gelatinase-associated lipocalin (NGAL; 1:2000; Abcam). All sections were incubated with Histofine® Simple Stain Mouse MAX PO(R) (Nichirei Biosciences, Tokyo, Japan) including the secondary antibody which is reduced to Fab fragment. Sections were developed with 3,3’-diaminobenzidine and counterstained with hematoxylin.
The tissue sections were exposed to the fluorescent antibody Alexa Fluor 546-conjugated anti-mouse IgG (Invitrogen, Carlsbad, CA, USA) after overnight incubation with the primary antibody according to the method in our previous study with minor modification . The nucleus was counterstained with Hoechst 33342 dye (Invitrogen). Immunofluorescence images were observed under an Olympus BX-51 fluorescence microscope (Olympus, Tokyo, Japan) and processed using Adobe Photoshop CC software (Adobe, San Jose, CA, USA).
Western blot analysis
After being removed and rinsed in sterilized PBS on ice, tissues were homogenized and then centrifuged at 18,000×g for 10 min at 4 °C, and the resulting supernatants were collected. When required, nuclear protein extracts from lungs were obtained with a commercially available nuclear extraction kit (Sigma-Aldrich, St. Louis, MO, USA), as described in the manufacturer’s manual. The proteins in the supernatant were measured using BCA Protein Assay Kit (Thermo Fisher Scientific, Rockford, IL, USA). Immunoblotting was performed as described in our previous reports [19, 23]. Samples (30–50 μg of protein) were electrophoresed on 10 or 14 % SDS-PAGEs and transferred to PVDF membrane. For primary antibody incubation (overnight at 4 °C), rabbit polyclonal or monoclonal antibodies were used against NGAL (1:1,000; Abcam), IκBα (1:1,000; Cell Signaling, Danvers, MA, USA), and phospho-IκBα (Ser-32) (1:1,000; Cell Signaling), whereas a mouse monoclonal antibody was used against nuclear factor (NF)-κB (1:200; Santa Cruz Biotechnology, Santa Cruz, CA, USA), β-actin (1:5,000; Wako Pure Chemical, Osaka, Japan), and GAPDH (1:5,000; Wako Pure Chemical) and a goat polyclonal antibody against lamin B (1:200; Santa Cruz Biotechnology). Primary antibody detection was performed with horseradish peroxidase-conjugated secondary antibodies. Binding of the antibody was detected by an ImmunoStar Zeta (Wako Pure Chemical), and levels of protein expression were quantitated by a luminoimage LAS-4000 analyzer (Fuji Film, Tokyo, Japan).
Values are expressed as means ± SEM. Statistical assessment of the data was made by Student’s unpaired t test or ANOVA followed by Tukey’s multiple comparison test using Prism software (ver. 7; GraphPad Software, San Diego, CA, USA). Differences at p < 0.05 were considered statistically significant.
Changes in tissue histamine concentrations, HDC expression, and histamine receptor expression after sepsis induction
Changes in histamine H1- and H2-receptor mRNA expression in the lung, liver, and kidney tissues of WT mice after sepsis induction were also examined by real-time PCR (Fig. 1b). In lung tissues, no increase in H1-receptor mRNA expression was observed after CLP. On the other hand, the mRNA levels were increased more than threefold in liver and kidney tissues at 6–12 h after CLP when compared with those shown in controls. Following induction of sepsis by CLP, a significant increase in H2-receptor mRNA expression was transiently detected in lung and liver tissues. In the kidney, CLP-induced sepsis resulted in a sustained, significant increase in the transcript level of H2-receptors.
Sepsis-induced inflammation and organ injury are alleviated in HDC knockout mice
Sepsis-induced NF-κB activation is reduced in HDC knockout mice
Sepsis-induced inflammation and organ injury are alleviated in H1-/H2-receptor double knockout mice
Effects of H1- and H2-receptor antagonists on sepsis-induced inflammation and organ injury
When CLP-induced septic mice received treatment with d-chlorpheniramine, famotidine, or both, the histological damage in the lungs was apparently minimized and the increase in MPO-positive cells was blunted by each treatment (Fig. 9b). In liver histology, d-chlorpheniramine, famotidine, or both showed a protective effect on liver damage caused by CLP-induced sepsis (Fig. 9b). The serum ALT levels, which were markedly increased at 18 h after sepsis induction, were reduced by treatment with each of d-chlorpheniramine and famotidine (Fig. 9c). In the kidneys, intense accumulation of immunoreactive NGAL that came along with sepsis remained unchanged with d-chlorpheniramine, but was attenuated by famotidine alone or combined with d-chlorpheniramine (Fig. 9b). Serum BUN and creatinine levels showed no difference between septic mice untreated and treated with d-chlorpheniramine, but famotidine treatment blunted the rise in the serum markers (Fig. 9c).
The specific pathophysiology and molecular basis of sepsis-associated multiple organ failure is still not fully understood. The updated definition of sepsis and septic shock has unveiled that organ dysfunction/failure is critical in determining the clinical outcome of sepsis . Here, we provide clear evidence that histamine is identified as an aggravating mediator to contribute to the development of major end-organ (that is, lung, liver, and kidney) injury in sepsis.
Circulating levels of histamine were significantly elevated in mice after induction of polymicrobial sepsis by CLP, as fully demonstrated in our previous report . This elevation in the circulating histamine levels was associated with increased tissue expression of HDC, an enzyme that only forms histamine in mammals. This could result in locally elevated levels of histamine concentrations in tissues. Indeed, we found that histamine levels elevated in the lung, liver, and kidney tissues in a time-dependent manner. In addition, the upregulation of gene expression levels of H1- and H2-receptors was observed after sepsis induction but quite varied between tissues. Taken together, these data shadow a possible role of histamine in the pathophysiology of sepsis.
Our CLP murine model of sepsis developed lung, liver, and kidney injury, as evidenced by histological changes, neutrophil filtration index, and biochemical variables. We found that sepsis-induced multiple organ injury was significantly attenuated in HDC−/− mice. This suggests that the lack of endogenous histamine could help to reduce sepsis-induced multiple organ injury. Alternatively, we interpret this finding to assume that histamine acts as a mediator to promote the development of multiple organ injury in sepsis. The attenuation of septic organ injury in HDC−/− mice may be partly the result of a reduction in cytokine production. Sepsis triggers overproduction of a diverse set of proinflammatory and chemotactic cytokines as demonstrated in this study. Their uncontrolled, exuberant production can be deleterious to various tissues and can lead to organ injury and dysfunction , although the pathogenesis of multiple organ dysfunction is multifactorial and is still being explored . In agreement with the present results on cytokines in HDC−/− mice, LPS-stimulated IL-6 production in liver tissues has been shown to fall to a low level in HDC−/− mice . Moreover, in vitro experiments have reported that histamine increases IL-6 production in B cells and glial cells , endothelial cells , and peripheral blood mononuclear cells , although there is found to be a report showing that histamine suppresses LPS-induced gene expression and synthesis of TNF-α in peripheral blood mononuclear cells mediated by H2-receptors .
However, our experiments with the H1-receptor antagonist d-chlorpheniramine and the H2-receptor antagonist famotidine indicate that the lessening of sepsis-induced organ injury observed in HDC−/− mice cannot be solely attributed to alterations in proinflammatory and chemotactic cytokine production. These antagonists were not necessarily effective in reducing some cytokines in blood, such as IL-1β and IL-6, which is inconsistent with their changes obtained in HDC−/− mice. Yet, both d-chlorpheniramine and famotidine were effective in reducing septic lung and liver injury, whereas famotidine, but not d-chlorpheniramine, mitigated septic kidney injury. This suggests that, while both H1- and H2-receptors are involved in lung and liver injury, only H2-receptors contribute to kidney injury in sepsis. The involvement of histamine via H1-receptors in lung vascular hyperpermeability in sepsis has been documented [9, 31]. H2-receptors have also been shown to be involved in the recruitment of neutrophils and protein leaks in LPS-induced acute lung injury . These adverse effects of histamine mediated by H1- and H2-receptors could be responsible for liver injury in sepsis. In renal ischemia/reperfusion injury, the beneficial effects of the H2-receptor antagonist ranitidine have been found to be partly mediated by decreased IL-6 production . Furthermore, it has been reported that mast cell-deficient mice exhibit attenuated acute kidney injury with cisplatin which is associated with reduced serum TNF-α levels and reduced recruitment of leukocytes to the inflamed kidney .
The transcription factor NF-κB has been well recognized as a pivotal player in the pathophysiology of sepsis . NF-κB is involved in regulating the transcription of many of the immunomodulatory mediators that can participate in the development of sepsis-induced organ failure . In a myriad of stimuli, commencing with endotoxin, IκBα is quickly phosphorylated, ubiquitinated, and degraded, releasing the NF-κB heterodimer, which then translocates from cytoplasm into nucleus to mediate the transcription of inflammatory genes. Interestingly, IκBα phosphorylation and degradation following CLP were impaired in lungs of HDC−/− mice. As a result, HDC−/− mice displayed low nuclear levels of NF-κB p65 in CLP-induced sepsis. We interpret these results to indicate that histamine can exert a facilitatory effect on activation of the NF-κB signaling pathway. Thus, histamine may help to promote the development of major end-organ injury in sepsis by enhancing NF-κB activity.
Contrary to the present findings indicative the role of H2-receptor activation in worsening septic liver injury, a previous report has demonstrated that histamine pretreatment can ameliorate D-galactosamine/LPS-induced liver injury in WT and H1-receptor knockout mice, but not H2-receptor knockout mice . Furthermore, histamine through H2-receptors has been documented to protect the liver against alcohol-induced injury in rats . It is difficult to reconcile these findings at present, but possible reasons for the apparent discrepancy may include different regulatory mechanisms between systemic vs. local inflammation and concentration-related differences between endogenous vs. exogenous histamine.
It is now well established that histamine exerts its biological effects by binding to and activating four distinct separate receptors: H1-, H2-, H3-, and H4-receptors . Although our experiments with d-chlorpheniramine and famotidine imply that H1- and H2-receptors are involved in the development of septic organ injury, we cannot entirely exclude that the lack of activation of H3- and H4-receptors may contribute to reduced organ injury in HDC−/− mice following sepsis. Interestingly, H4-receptors appear to play a role in sepsis-associated induction of apoptosis in the key organs . The exact role of H3- and H4-receptors in the pathophysiology of sepsis awaits further study using the animals deleted for their genes. It should be noted, however, that H1R−/−/H2R−/− mice displayed lesser degree of sepsis-related organ injuries as seen in HDC−/− mice.
Clinically, H1-receptor antagonists may be prescribed in perioperative settings, since many narcotics can induce itching . H2-receptor antagonists are widely used in critically ill patients to reduce the risk of gastrointestinal bleeding [40, 41]. Intriguingly, a significant risk for hospital-acquired pneumonia has been found for proton pump inhibitor (PPI) use but not H2-receptor antagonists in hospitalized patients , although the findings of an updated meta-analysis to evaluate the effects of PPIs vs. H2-receptor antagonists on clinically gastrointestinal bleeding in critically ill patients have shown no differences between drugs in the risk of pneumonia, death, or ICU length of stay . Whether H2-receptor antagonists vs. PPIs, when used for the prevention of gastrointestinal bleeding in the ICU, can differently affect the development of sepsis-associated organ failure awaits future clinical trials.
This study sheds light on the new role of histamine in the pathophysiology of sepsis. We represent the first report that endogenous histamine acting on H1- and H2-receptors is identified as an aggravating mediator to contribute to the development of major end-organ (that is, lung, liver, and kidney) injury in sepsis. While our present study suggests the benefit of their treatment in reducing sepsis disorder and supports that they may be safe medications in critically ill patients with sepsis, the validity and feasibility of the use of these histamine receptor antagonists to avoid the development of septic organ injury warrant further clinical investigations and evaluation.
The authors thank Nan Fukudo and Misuzu Nakamura for their expert technical assistance. They also thank Prof. Joji Imura for his valuable contribution to histological work and Prof. Toshimasa Toyo’oka for giving K.T. the opportunity to join this research project. This study was supported by Grant-in-Aids for Scientific Research (26460336) and for Challenging Exploratory Research (15 K15661) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.
MY, NM, and YH conceived and designed the experiments. MH, WO, ST, KT, TF, and HO performed the experiments. MH, WO, and TF analyzed the data. KH, NM, and YH wrote the paper. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Animal experimentation was performed according to national and institutional animal care and ethical guidelines and was approved by the local board.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
- Wang HE, Shapiro NI, Angus DC, Yealy DM (2007) National estimates of severe sepsis in Unites States emergency departments. Crit Care Med 35:1928–1936View ArticlePubMedGoogle Scholar
- Angus DC, van der Poll T (2013) Severe sepsis and septic shock. N Engl J Med 369:840–851View ArticlePubMedGoogle Scholar
- Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC (2016) The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 315:801–810View ArticlePubMedPubMed CentralGoogle Scholar
- Gustot T (2011) Multiple organ failure in sepsis: prognosis and role of systemic inflammatory response. Curr Opin Crit Care 17:153–159View ArticlePubMedGoogle Scholar
- Deutschman CS, Tracey KJ (2014) Sepsis: current dogma and new perspectives. Immunity 40:463–475View ArticlePubMedGoogle Scholar
- Rossaint J, Zarbock A (2015) Pathogenesis of multiple organ failure in sepsis. Crit Rev Immunol 35:277–291View ArticlePubMedGoogle Scholar
- Neugebauer E, Lorenz W, Rixen D, Stinner B, Sauer S, Dietz W (1996) Histamine release in sepsis: a prospective, controlled, clinical study. Crit Care Med 24:1670–1677View ArticlePubMedGoogle Scholar
- Matsuda N, Hattori Y, Sakuraya F, Kobayashi M, Zhang XH, Kemmotsu O, Gando S (2002) Hemodynamic significance of histamine synthesis and histamine H1- and H2-receptor gene expression during endotoxemia. Naunyn-Schmiedeberg’s Arch Pharmacol 366:513–521View ArticleGoogle Scholar
- Matsuda N, Hattori Y, Takahashi Y, Nishihira J, Jesmin S, Kobayashi M, Gando S (2004) Therapeutic effect of in vivo transfection of transcription factor decoy to NF-κB on septic lung in mice. Am J Physiol Lung Cell Mol Physiol 287:L1248–L1255View ArticlePubMedGoogle Scholar
- Matsuda N, Teramae H, Futatsugi M, Takano K, Yamamoto S, Tomita K, Suzuki T, Yokoo H, Koike K, Hattori Y (2010) Up-regulation of histamine H4 receptors contributes to splenic apoptosis in septic mice: Counteraction of antiapoptotic action of nuclear factor-κB. J Pharmacol Exp Ther 332:730–737View ArticlePubMedGoogle Scholar
- Matsuda N, Hattori Y, Zhang XH, Fukui H, Kemmotsu O, Gando S (2003) Contractions to histamine in pulmonary and mesenteric arteries from endotoxemic rabbits: modulation by vascular expression of inducible nitric-oxide synthase and histamine H1-receptors. J Pharmacol Exp Ther 307:175–181View ArticlePubMedGoogle Scholar
- Panula P, Chazot PL, Cowart M, Gutzmer R, Leurs R, Liu WL, Stark H, Thurmond RL, Haas HL (2015) International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors. Pharmacol Rev 67:601–655View ArticlePubMedPubMed CentralGoogle Scholar
- Hubbard WJ, Choudhry M, Schwacha MG, Kerby JD, Rue LW 3rd, Bland KI, Chaudry IH (2005) Cecal ligation and puncture. Shock 24(Suppl 1):52–57View ArticlePubMedGoogle Scholar
- Ohtsu H, Tanaka S, Terui T, Hori Y, Makabe-Kobayashi Y, Pejler G, Tchougounova E, Hellman L, Gertsenstein M, Hirasawa N, Sakurai E, Buzás E, Kovács P, Csaba G, Kittel A, Okada M, Hara M, Mar L, Numayama-Tsuruta K, Ishigaki-Suzuki S, Ohuchi K, Ichikawa A, Falus A, Watanabe T, Nagy A (2001) Mice lacking histidine decarboxylase exhibit abnormal mast cells. FEBS Lett 502:53–56View ArticlePubMedGoogle Scholar
- Inoue I, Yanai K, Kitamura D, Taniuchi I, Kobayashi T, Niimura K, Watanabe T, Watanabe T (1996) Impaired locomotor activity and exploratory behavior in mice lacking histamine H1 receptors. Proc Natl Acad Sci U S A 93:13316–13320View ArticlePubMedPubMed CentralGoogle Scholar
- Kobayashi T, Tonai S, Ishihara Y, Koga R, Okabe S, Watanabe T (2000) Abnormal functional and morphological regulation of the gastric mucosa in histamine H2 receptor-deficient mice. J Clin Invest 105:1741–1749View ArticlePubMedPubMed CentralGoogle Scholar
- Oishi H, Takano K, Tomita K, Takebe M, Yokoo H, Yamazaki M, Hattori Y (2012) Olprinone and colforsin daropate alleviate septic lung inflammation and apoptosis through CREB-independent activation of the Akt pathway. Am J Physiol Lung Cell Mol Physiol 303:L130–L140View ArticlePubMedGoogle Scholar
- Tomita K, Takashina M, Mizuno N, Sakata K, Hattori K, Imura J, Ohashi W, Hattori Y (2015) Cardiac fibroblasts: contributory role in septic cardiac dysfunction. J Surg Res 193:874–887View ArticlePubMedGoogle Scholar
- Wang Q, Yokoo H, Takashina M, Sakata K, Ohashi W, Abedelzaher LA, Imaizumi T, Sakamoto T, Hattori K, Matsuda N, Hattori Y (2015) Anti-inflammatory profile of levosimendan in cecal ligation-induced septic mice and in lipopolysaccharide-stimulated macrophages. Crit Care Med 43:e508–e520View ArticlePubMedGoogle Scholar
- Takano K, Yamamoto S, Tomita K, Takashina M, Yokoo H, Matsuda N, Takano Y, Hattori Y (2011) Successful treatment of acute lung injury with pitavastatin in septic mice: potential role of glucocorticoid receptor expression in alveolar macrophages. J Pharmacol Exp Ther 336:381–390View ArticlePubMedGoogle Scholar
- Yamatodani A, Fukuda H, Wada H, Iwaeda T, Watanabe T (1985) High-performance liquid chromatographic determination of plasma and brain histamine without previous purification of biological samples: cation-exchange chromatography coupled with pot-column derivatization fluorometry. J Chromatogr 344:115–123View ArticlePubMedGoogle Scholar
- Matsuda N, Hattori Y, Jesmin S, Gando S (2005) Nuclear factor-κB decoy oligodeoxynucleotides prevent acute lung injury in mice with cecal ligation and puncture-induced sepsis. Mol Pharmacol 67:1018–1025View ArticlePubMedGoogle Scholar
- Takebe M, Oishi H, Taguchi K, Aoki Y, Takashina M, Tomita K, Yokoo H, Takano Y, Yamazaki M, Hattori Y (2014) Inhibition of histone deacetylases protects septic mice from lung and splenic apoptosis. J Surg Res 187:559–570View ArticlePubMedGoogle Scholar
- Benjamin CF, Hagaboam CM, Kunkel SL (2004) The chronic consequences of severe sepsis. J Leukoc Biol 75:408–412View ArticleGoogle Scholar
- Wang H, Ma S (2008) The cytokine storm and factors determining the sequence and severity of organ dysfunction in multiple organ dysfunction syndrome. Am J Emerg Med 26:711–715View ArticlePubMedGoogle Scholar
- Horváth BV, Falus A, Tóth S, Szalai C, Lázár-Molnár E, Holub MC, Buzás E, Nagy A, Fulop AK (2002) Inverse regulation of interleukin-6 (IL-6) and IL-6 receptor in histamine deficient histidine decarboxylase-knock-out mice. Immunol Lett 80:151–154View ArticlePubMedGoogle Scholar
- Falus A (1993) Interleukin-6 biosynthesis is increased by histamine in human B-cell and glioblastoma cell lines. Immunology 78:193–196PubMedPubMed CentralGoogle Scholar
- Delneste Y, Lassalle P, Jeannin P, Joseph M, Tonnel AB, Gosset P (1994) Histamine induces IL-6 production by human endothelial cells. Clin Exp Immunol 98:344–349View ArticlePubMedPubMed CentralGoogle Scholar
- Mor S, Nagler A, Barak V, Handzel ZT, Geller-Bernstein C, Fabian I (1995) Histamine enhances granulocyte-macrophage colony-stimulating factor and interleukin-6 by human peripheral blood mononuclear cells. J Leukoc Biol 58:445–450PubMedGoogle Scholar
- Vannier E, Miller LC, Dinarello CA (1991) Histamine suppresses gene expression and synthesis of tumor necrosis factor α via histamine H2 receptors. J Exp Med 174:281–284View ArticlePubMedGoogle Scholar
- Brigham KL, Padove SJ, Bryant D, McKeen CR, Bowers RE (1980) Diphenhydramine reduces endotoxin effects on lung vascular permeability in sheep. J Appl Physiol 49:516–520PubMedGoogle Scholar
- Kim TH, Yoon HJ, Lim CM, Kim EK, Kim MJ, Koh Y (2005) The role of endogenous histamine on the pathogenesis of the lipopolysaccharide (LPS)-induced, acute lung injury: a pilot study. Inflammation 29:72–80View ArticlePubMedGoogle Scholar
- Vannay A, Fekete A, Müller V, Strehlau J, Viklicky O, Veres T, Reusz G, Tulassay T, Szabó AJ (2004) Effects of histamine and the h2 receptor antagonist ranitidine on ischemia-reperfusion acute renal failure: involvement of IL-6 and vascular endothelial growth factor. Kidney Blood Press Res 27:105–113View ArticlePubMedGoogle Scholar
- Summers SA, Chan J, Gan PY, Dewage L, Nozaki Y, Steinmetz OM, Nikolic-Paterson DJ, Kitching AR, Holdsworth SR (2011) Mast cells mediate acute kidney injury through the production of TNF. J Am Soc Nephrol 22:2226–2236View ArticlePubMedPubMed CentralGoogle Scholar
- Liu SF, Malik AB (2006) NF-κB activation as a pathological mechanism of septic shock and inflammation. Am J Physiol Lung Cell Mol Physiol 290:L622–L645View ArticlePubMedGoogle Scholar
- Abraham E (2003) Nuclear factor-kappaB and its role in sepsis-associated organ failure. J Infect Dis 187(Suppl 2):S364–S369View ArticlePubMedGoogle Scholar
- Masaki T, Chiba S, Tatsukawa H, Noguchi H, Kakuma T, Endo M, Seike M, Watanabe T, Yoshimatsu H (2005) The role of histamine H1 receptor and H2 receptor in LPS-induced liver injury. FASEB J 19:1245–1252View ArticlePubMedGoogle Scholar
- Hornyak SC, Gehlsen KR, Haaparanta T (2003) Histamine dihydrochloride protects against early alcohol-induced liver injury in a rat model. Inflammation 27:317–327View ArticlePubMedGoogle Scholar
- St Peter SD, Sharp SW, Ostlie DJ (2010) Influence of histamine receptor antagonists on the outcome of perforated appendicitis: analysis from a prospective trial. Arch Surg 145:143–146View ArticlePubMedGoogle Scholar
- Brett S (2005) Science review: The use of proton pump inhibitors for gastric acid suppression in critical illness. Crit Care 9:45–50View ArticlePubMedGoogle Scholar
- Marik PE, Vasu T, Hirani A, Pachinburavan M (2010) Stress ulcer prophylaxis in the new millennium: a systematic review and meta-analysis. Crit Care Med 38:2222–2228View ArticlePubMedGoogle Scholar
- Herzig SJ, Howell MD, Ngo LH, Marcantonio ER (2009) Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA 301:2120–2128View ArticlePubMedGoogle Scholar
- Alhazzani W, Alenezi F, Jaeschke RZ, Moayyedi P, Cook DJ (2013) Proton pump inhibitors versus histamine 2 receptor antagonists for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis. Crit Care Med 41:693–705View ArticlePubMedGoogle Scholar